[
  {
    "ts": "2025-11-20T13:12:01+00:00",
    "headline": "Bristol Myers Squibb Company (BMY) Slipped due to Lowered EPS Guidance",
    "summary": "Cullen Capital Management, LLC, operating under the name Schafer Cullen Capital Management, Inc. (SCCM), has released its “SCCM Value Equity Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. The US equity market continued the rally in the third quarter, with the S&P 500 returning 8.1% and the Russell 1000 Value surging 5.3%. […]",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-131201743.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "0740d4c7-9de6-3f51-9560-9e3e8b52b911",
      "content": {
        "id": "0740d4c7-9de6-3f51-9560-9e3e8b52b911",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Company (BMY) Slipped due to Lowered EPS Guidance",
        "description": "",
        "summary": "Cullen Capital Management, LLC, operating under the name Schafer Cullen Capital Management, Inc. (SCCM), has released its “SCCM Value Equity Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. The US equity market continued the rally in the third quarter, with the S&P 500 returning 8.1% and the Russell 1000 Value surging 5.3%. […]",
        "pubDate": "2025-11-20T13:12:01Z",
        "displayTime": "2025-11-20T13:12:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/5f20cdc6e9694860a75fcf45a32618af",
          "originalWidth": 768,
          "originalHeight": 430,
          "caption": "Scotiabank Initiates Coverage on Bristol Myers (BMY) with Sector Perform Rating and $45 Target",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WZTRF839CsopxcOyHv57Ug--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/5f20cdc6e9694860a75fcf45a32618af.cf.webp",
              "width": 768,
              "height": 430,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4s_q4.P5esjmvi8c7wRNPQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/5f20cdc6e9694860a75fcf45a32618af.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-131201743.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-131201743.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T13:00:52+00:00",
    "headline": "Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street.",
    "summary": "Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.",
    "url": "https://www.investors.com/news/technology/biotech-stocks-antibody-drug-conjugates-adcs-cancer-treatment-chemotherapy/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "f9b725a0-70ec-3d7c-b6ad-57019bb16362",
      "content": {
        "id": "f9b725a0-70ec-3d7c-b6ad-57019bb16362",
        "contentType": "STORY",
        "title": "Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street.",
        "description": "",
        "summary": "Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.",
        "pubDate": "2025-11-20T13:00:52Z",
        "displayTime": "2025-11-20T13:00:52Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f9b725a0-70ec-3d7c-b6ad-57019bb16362/fighting-cancer-with-smart.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/df85f837a66d5261ed75b0c3cb5c22a5",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CKNC14_xKnnkfusozx52rQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/df85f837a66d5261ed75b0c3cb5c22a5.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CipNqaIpEDaOj._ohoVSnw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/df85f837a66d5261ed75b0c3cb5c22a5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/biotech-stocks-antibody-drug-conjugates-adcs-cancer-treatment-chemotherapy/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "ROG.SW"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T14:19:55+00:00",
    "headline": "The Tech Rotation Is On and Dividend-Paying Blue-Chips Are the Winners",
    "summary": "These six top blue-chip dividend stocks remain outstanding ideas for investors seeking to move away from tech stocks.",
    "url": "https://247wallst.com/investing/2025/11/20/the-tech-rotation-is-on-and-dividend-paying-blue-chips-are-the-winners/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "c68c7164-6abb-3879-8835-eb96c89426cc",
      "content": {
        "id": "c68c7164-6abb-3879-8835-eb96c89426cc",
        "contentType": "STORY",
        "title": "The Tech Rotation Is On and Dividend-Paying Blue-Chips Are the Winners",
        "description": "",
        "summary": "These six top blue-chip dividend stocks remain outstanding ideas for investors seeking to move away from tech stocks.",
        "pubDate": "2025-11-20T14:19:55Z",
        "displayTime": "2025-11-20T14:19:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/2c6f1ac5a964ca7ee62b57d97fbadb89",
          "originalWidth": 1366,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PsbiSw525O0AwUWj.X1wvA--~B/aD03Njg7dz0xMzY2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/2c6f1ac5a964ca7ee62b57d97fbadb89.cf.webp",
              "width": 1366,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hHGjTC_8PZAZZT1tNDpfmA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/2c6f1ac5a964ca7ee62b57d97fbadb89.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/11/20/the-tech-rotation-is-on-and-dividend-paying-blue-chips-are-the-winners/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tech-rotation-dividend-paying-blue-141955486.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PG"
            },
            {
              "symbol": "CVX"
            },
            {
              "symbol": "T"
            },
            {
              "symbol": "T-PA"
            },
            {
              "symbol": "JPM"
            },
            {
              "symbol": "META"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "ORCL"
            },
            {
              "symbol": "KO"
            },
            {
              "symbol": "AMZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T13:00:00+00:00",
    "headline": "This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.",
    "summary": "For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date.  It’s a challenge that  Bristol Myers Squibb  is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022.  Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.",
    "url": "https://www.barrons.com/articles/wp-bar-0001507322?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "8c561c75-a147-385f-98d0-4c38e35872d0",
      "content": {
        "id": "8c561c75-a147-385f-98d0-4c38e35872d0",
        "contentType": "STORY",
        "title": "This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.",
        "description": "",
        "summary": "For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date.  It’s a challenge that  Bristol Myers Squibb  is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022.  Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.",
        "pubDate": "2025-11-20T13:00:00Z",
        "displayTime": "2025-11-20T13:00:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8c561c75-a147-385f-98d0-4c38e35872d0/this-drugmaker-is-too-cheap.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/dfaa0aa278f6a97780dafb57ba7fcc4e",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BDAtWtLWyCI7CySX9RsC6g--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/dfaa0aa278f6a97780dafb57ba7fcc4e.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u1UI6uVhsex1XVTnmmR5iA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/dfaa0aa278f6a97780dafb57ba7fcc4e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/wp-bar-0001507322?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "SNYNF"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T18:10:00+00:00",
    "headline": "Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?",
    "summary": "BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.",
    "url": "https://finance.yahoo.com/news/librexia-acs-study-setback-dent-181000829.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "74ea53f2-b3f7-3dee-b2a2-a49ba385a61f",
      "content": {
        "id": "74ea53f2-b3f7-3dee-b2a2-a49ba385a61f",
        "contentType": "STORY",
        "title": "Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?",
        "description": "",
        "summary": "BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.",
        "pubDate": "2025-11-20T18:10:00Z",
        "displayTime": "2025-11-20T18:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/librexia-acs-study-setback-dent-181000829.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/librexia-acs-study-setback-dent-181000829.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]